However, several other glucose lowering agents, including sulfonylureas, thiazolidinediones, and insulin, do not reduce CV events [32], despite clear evidence that hyperglycaemia increases the risk of ASCVD events [33,34]. The gene discussed is INS; the disease is atherosclerosis.